Condition: Cancer · Multi Cancer Early Screening · Liquid Biopsy · Sponsor: Nanjing Shihejiyin Technology, Inc.
The Jinling Cohort is a prospective, multicenter cohort study in which 15,000 eligible individuals aged 45-75 in Nanjing China will be enrolled.
This description comes directly from the study's public registry record.
Shanshan Yang, Ph.D · 8613585145836 · admin@geneseeq.com
Xuan Wang · 8618392411194 · cohortstudy@geneseeq.com
Always discuss trial participation with your own doctor first.
| Nanjing Jiangbei People's Hospital | Nanjing, Jiangsu, China | Recruiting |
| The Fourth Affiliated Hospital of Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06011694